Compare Etsy Inc (ETSY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs ResMed Inc. — how do they compare? Etsy Inc trades at $79.42 (market cap $7.29B), while ResMed Inc. trades at $224.99 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 4.5× Etsy Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | RMD | |
|---|---|---|
Market Cap | $7.29B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.47 | $293.73 |
52-Week Low | $44.05 | $182.82 |
Enterprise Value | $9.25B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $80.40, down 6.02% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $0.98 beating expectations of $0.747, while announcing a 12% workforce reduction and $2 billion share repurchase program. Revenue trends show modest growth from $2.6B in 2022 to $2.9B in 2025, though net income margins have compressed from 11.19% in 2023 to 5.65% in 2025.
The outlook remains mixed with analyst consensus at Buy (46.7%) versus Hold (46.7%) and an $85.71 price target offering 6.6% upside. Key risks include high debt levels ($2.29B long-term debt), competitive pressures, and execution of restructuring. Positive catalysts include AI integration progress and operational efficiency improvements driving GMS growth acceleration to 7.5% year-over-year.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
